H.C. Wainwright analyst Mitchell Kapoor says private company Kelonia Therapeutics reported early in vivo CAR-T data that showed no detectable cancer cells in all three treated patients and “robust” CAR-T expansion without lymphodepletion. The data pressured valuations across the B-cell maturation antigen space, the analyst tells investors in a research note. However, H.C. Wainwright believes Kelonia’s dataset remains “extremely small” and “far from” clinically comparable to a commercial-stage CAR-T. It sees little readthrough to Legend Biotech’s (LEGN) Carvykti and reiterates a Buy rating on the shares with a $60 price target Legend’s competitive fears are overdone, the firm contends.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Buy Rating for Legend Biotech Reaffirmed Due to CARVYKTI’s Strong Market Position and Proven Efficacy
- Legend Biotech price target raised to $75 from $66 at Cantor Fitzgerald
- Legend Biotech price target lowered to $90 from $94 at Barclays
- Legend Biotech’s Q3 2025: Strong CARVYKTI® Sales
- Legend Biotech’s Earnings Call Highlights Growth and Challenges